Start with OPSUMIT® (macitentan) to reduce the risks of disease progression and hospitalization for PAH1

In the treatment of pulmonary arterial hypertension (PAH, WHO Group I)

OPSUMIT® campaign
Contact your
Local MSL
Request A Medical Science
Liaison (MSL)
Contact your
Local MSL
Request A Medical Science
Liaison (MSL)

Individual patient experience may vary. OPSUMIT® has a 9-year long-term safety, tolerability, and survival open-label extension study in patients with PAH.1

Learn more about OPSUMIT® clinical data

View overall results from the SERAPHIN pivotal trial

Explore an additional OPSUMIT® analysis

Read about the REPAIR study

See SERAPHIN PAH-related hospitalization data

View PAH-related hospitalization data

Need downloadable resources?

View our library of downloadable materials for HCPs and patients

Explore SERAPHIN PAH-CTD subgroup data

View PAH-CTD subgroup post hoc analyses

Watch patient and HCP perspectives on PAH

Access the video library


HCP=healthcare professional; PAH=pulmonary arterial hypertension; PAH-CTD=PAH associated with connective tissue disease; REPAIR=Right vEntricular remodeling in Pulmonary ArterIal hypeRtension; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve CliNical Outcome; WHO=World Health Organization.
Reference: 1. Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390


+ +